secukinumab 150 mg

DRUG8 trials

Sponsors

Novartis Pharmaceuticals, Peking Union Medical College Hospital

Conditions

Giant Cell Arteritis (GCA)Moderate to Severe Chronic Plaque-type PsoriasisModerate to Severe Palmoplantar PsoriasisModerate to Severe Plaque-type PsoriasisPolymyalgia RheumaticaPsoriatic Arthritis

Phase 1

An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients

Peking Union Medical College HospitalPsoriatic Arthritis

Start: 2021-07-15End: 2022-12-31Target: 60Updated: 2021-07-20

Phase 3

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

CompletedNCT01365455

Novartis PharmaceuticalsModerate to Severe Plaque-type Psoriasis

Start: 2011-06-30End: 2013-04-30Updated: 2021-01-05

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

CompletedNCT01555125

Novartis PharmaceuticalsModerate to Severe Plaque-type Psoriasis

Start: 2012-05-08End: 2016-10-24Updated: 2018-08-08

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

CompletedNCT01806597

Novartis PharmaceuticalsModerate to Severe Palmoplantar Psoriasis

Start: 2013-06-19End: 2016-11-02Updated: 2018-02-22

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

CompletedNCT03504852

Novartis PharmaceuticalsModerate to Severe Chronic Plaque-type Psoriasis

Start: 2018-06-25End: 2020-07-15Updated: 2021-10-11

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

CompletedNCT04930094

Novartis PharmaceuticalsGiant Cell Arteritis (GCA)

Start: 2021-10-06End: 2026-02-18Updated: 2026-03-31

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

CompletedNCT05767034

Novartis PharmaceuticalsPolymyalgia Rheumatica

Start: 2023-03-22End: 2026-02-16Updated: 2026-06-22

Phase 4

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

CompletedNCT02798211

Novartis PharmaceuticalsPsoriatic Arthritis

Start: 2016-06-27End: 2018-12-05Updated: 2021-10-07

Related Papers

Secukinumab for Giant Cell Arteritis.

2026-06-03

Efficacy of Secukinumab in Patients With Mild to Moderate Psoriasis: A Pooled Analysis of 6 Phase 3 Studies

SKIN The Journal of Cutaneous Medicine2023-11-13

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.

2023-06-216 citations

Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study

Pediatric Drugs2022-06-1317 citations

Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study

The Journal of Rheumatology2022-04-1514 citations

Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications

Rheumatology and Therapy2022-03-1933 citations

Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*

British Journal of Dermatology2022-01-0445 citations

Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab.

2021-06-1010 citations

Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis—a <i>post-hoc</i> analysis of pooled data from three phase 3 trials with secukinumab

Rheumatology Advances in Practice2021-01-015 citations

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

Journal of the European Academy of Dermatology and Venereology2020-05-0442 citations

Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials.

2020-01-034 citations

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.

2019-10-1055 citations

Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis

Journal of Dermatological Treatment2019-07-0954 citations

Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

Journal of the European Academy of Dermatology and Venereology2019-04-2231 citations

Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies

Dermatology and Therapy2016-08-3027 citations

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies

Dermatology and Therapy2016-08-3017 citations

Secukinumab efficacy and safety in Japanese patients with moderate‐to‐severe plaque psoriasis: Subanalysis from <scp>ERASURE</scp>, a randomized, placebo‐controlled, phase 3 study

The Journal of Dermatology2014-10-3089 citations

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

New England Journal of Medicine2014-07-091925 citations